Gastrointestinal Disorders: Innovative Pipeline Offers Potential for First Approved Therapies in NASH and Celiac Disease

Publisher Name :
Date: 08-Mar-2019
No. of pages: 165

Gastrointestinal Disorders: Innovative Pipeline Offers Potential for First Approved Therapies in NASH and Celiac Disease

Summary

The burden of disease associated with gastrointestinal disorders is considerable with many of these disorders being highly prevalent. Additionally, many GI disorders are chronic in nature and are associated with significant impairments in quality of life including activity impairment and productivity loss. Despite this, many of these conditions are still incompletely understood and suboptimally managed. Therefore, there is a considerable unmet need for innovative new therapies in this area. This report assesses first-in-class innovation across the gastrointestinal therapy area, with a particular focus on four key indications: Crohn's disease, ulcerative colitis, nonalcoholic steatohepatitis and celiac disease.

Scope

- Many gastrointestinal disorders are highly prevalent. How do epidemiology trends vary for Crohn's disease, ulcerative colitis, nonalcoholic steatohepatitis and celiac disease? Which drug classes are used to treat these disorders?

- There are 1,241 pipeline programs in active development for gastrointestinal disorders. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class?

- First-in-class products within the pipeline most frequently target cytokine signaling. Which other molecular target classes are prominently represented within the first-in-class pipeline? Which first-in-class targets have been identified as most promising for gastrointestinal disorders?

- A total of 573 licensing deals and 334 co-development deals have been completed within the gastrointestinal therapy area since 2006. Do products for gastrointestinal products typically attract high deal values? Which first-in-class products have prior deal involvement?

Reasons to buy

- Understand the current clinical and commercial landscape. This includes a comprehensive study of symptoms, epidemiology, etiology, pathophysiology, co-morbidities and complications, diagnosis and treatment options for the key indications.

- Visualize the composition of the gastrointestinal market in terms of dominant molecule types and molecular targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.

- Analyze the gastrointestinal pipeline and stratify by stage of development, molecule type and molecular target.

- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products for the key indications have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.

- Recognize commercial opportunities in the gastrointestinal deals landscape by analyzing trends in licensing and co-development deals, and identifying gastrointestinal therapies that have not yet been involved in deals and may offer potential investment opportunities.

Gastrointestinal Disorders: Innovative Pipeline Offers Potential for First Approved Therapies in NASH and Celiac Disease

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Gastrointestinal Disorders Associated with Large Social and Economic Burden
2.2 Large First-in-Class Pipeline with Many Promising Targets Implicated in Immune and Inflammatory Responses
2.3 The Majority of First-in-Class Products Have No Prior Involvement in Licensing or Co-development Deals
3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation
3.5 Sustained Innovation in Gastrointestinal Disorders
3.6 Report Guidance
4 Clinical and Commercial Landscape
4.1 Overview of Gastrointestinal Tract Disorders
4.2 Symptoms
4.3 Diagnosis
4.4 Etiology
4.5 Pathophysiology
4.6 Epidemiology
4.7 Co-morbidities and Complications
4.8 Disease Staging
4.9 Treatment
4.10 Overview of Marketed Products
5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class
5.5 First-in-Class Programs Targeting Novel Molecular Targets
5.6 Ratio of First-in-Class Products to First-in-Class Targets
5.7 List of All Pipeline Products
6 Signaling Network, Disease Causation and Innovation Alignment
6.1 Complexity of Signaling Networks
6.2 Signaling Pathways and First-in-Class Molecular Target Integration
6.3 First-in-Class Matrix Assessments
7 First-in-Class Molecular Target Evaluation
7.1 Pipeline Programs Targeting Non Receptor Tyrosine Protein Kinase TYK2 for Crohn's Disease and Ulcerative Colitis
7.2 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5 for Crohn's Disease and Ulcerative Colitis
7.3 Pipeline Programs Targeting Interleukin 7 Receptor Subunit Alpha for Crohn's Disease and Ulcerative Colitis
7.4 Pipeline Programs Targeting Prostaglandin E2 Receptor EP4 for Ulcerative Colitis
7.5 Pipeline Programs Targeting Adiponectin for Nonalcoholic Steatohepatitis
7.6 Pipeline Programs Targeting Toll-like Receptor 4 for Nonalcoholic Steatohepatitis and Crohn's Disease
7.7 Pipeline Programs Targeting Protease Activated Receptor 2 for Celiac Disease and Nonalcoholic Steatohepatitis
7.8 Pipeline Programs Targeting Interleukin 2 Receptor Subunit Beta for Celiac Disease
8 Strategic Consolidations
8.1 Industry-wide First-in-Class Deals
8.2 Licensing Deals
8.3 Co-development Deals
8.4 First-in-Class Programs with and without Prior Licensing or Co-development Deal Involvement
9 Appendix
9.1 References
9.2 Abbreviations
9.3 Pipeline Disease List
9.4 Methodology
9.5 Secondary Research
9.6 Contact Us
9.7 Disclaimer

1.1 List of Tables
Table 1: Gastrointestinal Disorders, Global, Crohn's Disease Diagnostic Features, 2014
Table 2: Gastrointestinal Disorders, Global, Mayo Score for Ulcerative Colitis, 2017
Table 3: Gastrointestinal Disorders, Global, Summary of Montreal and Paris Classification for Crohn's Disease, 2014
Table 4: Gastrointestinal Disorders, Global, Montreal Classification of Extent and Severity for Ulcerative Colitis, 2005
Table 5: Gastrointestinal Disorders, Global, Categories of Nonalcoholic Fatty Liver Disease, 2019
Table 6: Gastrointestinal Disorders, Global, Nonalcoholic Fatty Liver Disease Activity Score (NAS), 2019
Table 7: Gastrointestinal Disorders, Global, Modified Marsh Classification of Histologic Findings in Celiac Disease, 2018
Table 8: Gastrointestinal Disorders, Global, Key Features of Non Receptor Tyrosine Protein Kinase TYK2, 2019
Table 9: Gastrointestinal Disorders, Global, Pipeline Programs Targeting Non Receptor Tyrosine Protein Kinase TYK2, 2019
Table 10: Gastrointestinal Disorders, Global, Key Features of Tumor Necrosis Factor Receptor Superfamily Member 5, 2019
Table 11: Gastrointestinal Disorders, Global, Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5, 2019
Table 12: Gastrointestinal Disorders, Global, Key Features of Interleukin 7 Receptor Subunit Alpha, 2019
Table 13: Gastrointestinal Disorders, Global, Key Features of Interleukin 7 Receptor Subunit Alpha, 2019
Table 14: Gastrointestinal Disorders, Global, Key Features of Prostaglandin E2 receptor EP4 subtype, 2019
Table 15: Gastrointestinal Disorders, Global, Pipeline Programs Targeting Prostaglandin E2 Receptor EP4 Subtype, 2019
Table 16: Gastrointestinal Disorders, Global, Key Features of Adiponectin, 2019
Table 17: Gastrointestinal Disorders, Global, Pipeline Programs Targeting Adiponectin, 2019
Table 18: Gastrointestinal Disorders, Global, Key Features of Toll-Like Receptor 4, 2019
Table 19: Gastrointestinal Disorders, Global, Pipeline Programs Targeting Toll-Like Receptor 4, 2019
Table 20: Gastrointestinal Disorders, Global, Key Features of Proteinase Activated Receptor 2, 2019
Table 21: Gastrointestinal Disorders, Global, Pipeline Programs Targeting Proteinase Activated Receptor 2, 2019
Table 22: Gastrointestinal Disorders, Global, Key Features of Interleukin 2 Receptor Subunit Beta, 2019
Table 23: Gastrointestinal Disorders, Global, Pipeline Programs Targeting Interleukin 2 Receptor Subunit Beta, 2019

1.2 List of Figures
Figure 1: Gastrointestinal Disorders, US, Innovation Trends in Product Approvals Across the Pharmaceutical Market, 1987-2014
Figure 2: Gastrointestinal Disorders, US, Post-Marketing-Approval Sales Performance of First-in-Class Products Across the Pharmaceutical Industry ($m), 2006-2013
Figure 3: Gastrointestinal Disorders, Global, Market by Molecule Type, 2019
Figure 4: Gastrointestinal Disorders, Global, Market by Molecular Target Class, 2019
Figure 5: Gastrointestinal Disorders, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2019
Figure 6: Gastrointestinal Disorders, Global, Pipeline by Stage of Development and Molecule Type, 2019
Figure 7: Gastrointestinal Disorders, Global, Pipeline for Key Indications by Stage of Development, 2019
Figure 8: Gastrointestinal Tract Disorders, Global, Pipeline for Key Indications by Molecule Type, 2019
Figure 9: Gastrointestinal Disorders, Global, Pipeline by Molecular Target Class and Stage of Development, 2019
Figure 10: Gastrointestinal Disorders, Global, Breakdown of Cytokine Signaling, GPCR and Transcription Factor and Regulation Molecular Target Classes, 2019
Figure 11: Gastrointestinal Disorders, Global, Pipeline for Key Indications by Molecular Target Class, 2019
Figure 12: Gastrointestinal Disorders, Global, Pipeline and Marketed Products by Molecular Target Class, 2019
Figure 13: Gastrointestinal Disorders, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2019
Figure 14: Gastrointestinal Disorders, Global, Pipeline for Key Indications by Molecular Target Class and First-in-Class Status, 2019
Figure 15: Gastrointestinal Disorders, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development and Molecular Target Class (%), 2019
Figure 16: Gastrointestinal Disorders, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
Figure 17: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 1)
Figure 18: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 2)
Figure 19: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 3)
Figure 20: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 4)
Figure 21: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 5)
Figure 22: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 6)
Figure 23: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 7)
Figure 24: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 8)
Figure 25: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 9)
Figure 26: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 10)
Figure 27: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 11)
Figure 28: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 12)
Figure 29: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 13)
Figure 30: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Crohn's Disease, 2019 (part 1)
Figure 31: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Crohn's Disease, 2019 (part 2)
Figure 32: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Ulcerative Colitis, 2019 (part 1)
Figure 33: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Ulcerative Colitis, 2019 (part 2)
Figure 34: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Nonalcoholic Steatohepatitis, 2019 (part 1)
Figure 35: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Nonalcoholic Steatohepatitis, 2019 (part 2)
Figure 36: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Nonalcoholic Steatohepatitis, 2019 (part 3)
Figure 37: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Nonalcoholic Steatohepatitis, 2019 (part 4)
Figure 38: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Celiac Disease, 2019
Figure 39: Gastrointestinal Disorders, Global, Industry-Wide Licensing Deals by First-in-Class Status and Stage of Development, 2006-2014
Figure 40: Gastrointestinal Disorders, Global, Industry-Wide Licensing Deals by First-in-Class Status, Deal Value, Upfront Payment Value and Stage of Development, 2006-2014
Figure 41: Gastrointestinal Disorders, Global, Licensing Deals by Region, Value and Year, 2006-2019
Figure 42: Gastrointestinal Disorders, Global, Licensing Deals by Key Indication, 2006-2019
Figure 43: Gastrointestinal Disorders, Global, Licensing Deals by Stage of Development, Deal Value, and Upfront Payment Value ($m), 2006-2019
Figure 44: Gastrointestinal Disorders, Global, Licensing Deals by Molecule Type and Molecular Target Class, 2006-2019
Figure 45: Gastrointestinal Disorders, Global, Licensing Deals with Disclosed Deal Values, 2006-2019 (part 1)
Figure 46: Gastrointestinal Disorders, Global, Licensing Deals with Disclosed Deal Values, 2006-2019 (part 2)
Figure 47: Gastrointestinal Disorders, Global, Licensing Deals with Disclosed Deal Values, 2006-2019 (part 3)
Figure 48: Gastrointestinal Disorders, Global, Licensing Deals with Disclosed Deal Values, 2006-2019 (part 4)
Figure 49: Gastrointestinal Disorders, Global, Co-development Deals by Region, Value and Year, 2006-2019
Figure 50: Gastrointestinal Disorders, Global, Co-development Deals by Key Indication, 2006-2019
Figure 51: Gastrointestinal Disorders, Global, Co-development Deals by Stage of Development and Deal Value, 2006-2019
Figure 52: Gastrointestinal Disorders, Global, Co-development Deals by Molecule Type and Molecular Target Class, 2006-2019
Figure 53: Gastrointestinal Disorders, Global, Co-development Deals with Disclosed Deal Values, 2006-2019 (part 1)
Figure 54: Gastrointestinal Disorders, Global, Co-development Deals with Disclosed Deal Values, 2006-2019 (part 2)
Figure 55: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 1)
Figure 56: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 2)
Figure 57: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 3)
Figure 58: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 4)
Figure 59: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 5)
Figure 60: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 6)
Figure 61: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 7)
Figure 62: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 8)
Figure 63: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 9)
Figure 64: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 10)
Figure 65: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 11)
Figure 66: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 12)
Figure 67: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 13)
  • Global and China Irritable Bowel Syndrome (IBS) Market Research by Company, Type & Application 2013-2025
    Published: 12-Aug-2019        Price: US 2000 Onwards        Pages: 76
    Summary Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled internat......
  • Global (United States, European Union and China) Laxatives Market Research Report 2019-2025
    Published: 09-Aug-2019        Price: US 3280 Onwards        Pages: 116
    Laxatives are substances that loosen stools and increase bowel movements. They are used to treat and/or prevent constipation. Laxatives vary as to how they work and the side effects they may have. Bulk-forming laxatives, also known as roughage, are substances, such as fiber in food and hydrophilic agents in over-the-counter drugs, that add bulk and water to stools so that they can pass more easily through the intestines (lower part of the digestive tract). Emollient laxatives, also known ......
  • Lansoprazole Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 07-Aug-2019        Price: US 3000 Onwards        Pages: 137
    Lansoprazole Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Lansoprazole industry with a focus on the Chinese market. The report provides key statistics on the market status of the Lansoprazole manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese Lansoprazole market coverin......
  • Global (United States, European Union and China) Gastrointestinal Drugs Market Research Report 2019-2025
    Published: 02-Aug-2019        Price: US 3280 Onwards        Pages: 114
    Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders. In 2019, the market size of Gastrointestinal Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will inc......
  • Esomeprazole Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 29-Jul-2019        Price: US 3000 Onwards        Pages: 142
    Esomeprazole Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Esomeprazole industry with a focus on the Chinese market. The report provides key statistics on the market status of the Esomeprazole manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese Esomeprazole market coverin......
  • Glycopyrrolate Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 26-Jul-2019        Price: US 3000 Onwards        Pages: 138
    Glycopyrrolate Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Glycopyrrolate industry with a focus on the Chinese market. The report provides key statistics on the market status of the Glycopyrrolate manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese Glycopyrrolate market......
  • Global Irritable Bowel Syndrome (IBS) Market Status (2015-2019) and Forecast (2020-2024) by Region, Product Type & End-Use
    Published: 21-Jul-2019        Price: US 3000 Onwards        Pages: 108
    Summary Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled internat......
  • Global (United States, European Union and China) Inflammatory Bowel Disease Drugs Market Research Report 2019-2025
    Published: 18-Jul-2019        Price: US 3280 Onwards        Pages: 110
    Inflammatory bowel disease is a condition generally caused when immune system attacks harmless bacteria, virus, or food in the intestine. The most common inflammatory bowel diseases are ulcerative colitis and Crohns disease. The growth in prevalence of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease majorly drives the growth of the market. In addition, increase in intake of unhealthy food and drinks, and sedentary and stressful lifestyle propels the growth of t......
  • Global Irritable Bowel Syndrome (IBS) Market Research Report 2012-2024
    Published: 17-Jul-2019        Price: US 1870 Onwards        Pages: 84
    Summary Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled internat......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs